IMCnyeso
- Generic Name
- IMCnyeso
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 29
- Registration Number
- NCT03515551
- Locations
- 🇺🇸
Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
🇺🇸University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath